{{Link style|time=2015-12-11T07:17:06+00:00}}
{{medical}}
{{Drugbox
| verifiedrevid = 459476800
| IUPAC_name = ''N''-(hexahydrocyclopenta[''c'']pyrrol-2(1''H'')-ylcarbamoyl)-4-methylbenzenesulfonamide
| image = Gliclazide.svg
| image2 = Gliclazide ball-and-stick.png
<!--Clinical data-->
| tradename =达美康
| Drugs.com = {{drugs.com|CONS|gliclazide}}
| pregnancy_AU = C
| legal_AU = S4
| routes_of_administration = 口服
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life = 10.4小时
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 21187-98-4
| ATC_prefix = A10
| ATC_suffix = BB09
| PubChem = 3475
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01120
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3356
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = G4PX8C4HKV
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01599
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 31654
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 427216
<!--Chemical data-->
| C=15 | H=21 | N=3 | O=3 | S=1
| molecular_weight = 323.412 [[Gram|g]]/[[Mole_(unit)|mol]]
| smiles = O=S(=O)(c1ccc(cc1)C)NC(=O)NN3CC2CCCC2C3
| InChI = 1/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
| InChIKey = BOVGTQGAOIONJV-UHFFFAOYAB
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BOVGTQGAOIONJV-UHFFFAOYSA-N
}}
'''格列齐特'''（{{lang-en|Gliclazide}}），商品名为'''达美康'''。是一种[[磺酰脲类|磺酰脲类]]口服[[抗糖尿病药|抗糖尿病药]]。 <ref name="pmid2106423">{{cite journal |pages=109–14 |doi=10.1016/0168-8227(90)90020-T |title=Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds |url=https://archive.org/details/sim_diabetes-research-and-clinical-practice_1990_8_2/page/109 |year=1990 |last1=Ballagi-Pordány |first1=György |last2=Köszeghy |first2=Anna |last3=Koltai |first3=Mária-Zsófia |last4=Aranyi |first4=Zoltán |last5=Pogátsa |first5=Gábor |journal=Diabetes Research and Clinical Practice |volume=8 |issue=2 |pmid=2106423}}</ref><ref>{{cite journal |pages=722–30 |doi=10.1016/j.metabol.2006.01.019 |title=Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation |year=2006 |last1=Shimoyama |first1=Tatsuhiro |last2=Yamaguchi |first2=Shinya |last3=Takahashi |first3=Kazuto |last4=Katsuta |first4=Hidenori |last5=Ito |first5=Eisuke |last6=Seki |first6=Hiroyuki |last7=Ushikawa |first7=Kenji |last8=Katahira |first8=Hiroshi |last9=Yoshimoto |first9=Katsuhiko |last10=Ohno |first10=Hideki |last11=Nagamatsu |first11=Shinya |last12=Ishida |first12=Hitoshi |journal=Metabolism |volume=55 |issue=6 |pmid=16713429|display-authors=8 }}</ref>. 格列齐特可以防止因高血糖引起的[[细胞凋亡|细胞凋亡]]，保护人体的[[胰岛|胰岛β细胞]]。<ref>{{cite journal |pages=234–8 |doi=10.1002/dmrr.680 |title=Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose |year=2007 |last1=Del Guerra |first1=S |last2=Grupillo |first2=M |last3=Masini |first3=M |last4=Lupi |first4=R |last5=Bugliani |first5=M |last6=Torri |first6=S |last7=Boggi |first7=U |last8=Del Chiaro |first8=M |last9=Vistoli |first9=F |last10=Mosca |first10=F |last11=Del Prato |first11=S |last12=Marchetti |first12=P |journal=Diabetes/Metabolism Research and Reviews |volume=23 |issue=3 |pmid=16952202|display-authors=8 }}</ref> 格列齐特还可以防止因[[2型糖尿病|2型糖尿病]]导致的[[动脉粥样硬化|动脉粥样硬化]]（防止动脉脂肪堆积）。<ref>{{cite journal |pages=1906–13 |doi=10.1007/s00125-004-1547-8 |title=Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes |year=2004 |last1=Katakami |first1=N. |last2=Yamasaki |first2=Y. |last3=Hayaishi-Okano |first3=R. |last4=Ohtoshi |first4=K. |last5=Kaneto |first5=H. |last6=Matsuhisa |first6=M. |last7=Kosugi |first7=K. |last8=Hori |first8=M. |journal=Diabetologia |volume=47 |issue=11 |pmid=15565373}}</ref>格列齐特在中国作为一线药物使用，应用极为广泛，而在其他国家却并不常用。Diamicron ( Gliclazide)

==药理==
格列齐特为[[胰島素|胰島素]]增秘剂，通过抑制[[胰岛|胰岛β细胞]]的[[:en:ATP-sensitive_potassium_channel|K<sub>ATP</sub>]]通道，从而促进胰岛素的释放。

==引用==
{{reflist}}

{{-}}

{{口服降糖药和胰岛素类似物}}
{{Diabetes}}

[[Category:糖尿病药物|Category:糖尿病药物]]
[[Category:对甲苯磺酰基化合物|Category:对甲苯磺酰基化合物]]